Evidence map›Paper›PMID 29572500›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy.

Sergio Matarraz, Pilar Leoz, Carlos Fernández, Enrique Colado, María Carmen Chillón, María Belén Vidriales, Marcos González, Daniel Rivera, Carlos Salvador Osuna, Teresa Caballero-Velázquez and 18 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Basophils in Acute Promyelocytic Leukemia: Clonality or Reactiveness?Turkish journal of haematology : official journal of Turkish Society of Haematology · 2025
    Article
  3. Review
  4. Article
  5. Acute Promyelocytic Leukemia with Basophilic Differentiation: A Rare VariantTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 14 institutions in 2 countries.

Sergio MatarrazCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Pilar LeozCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Carlos FernándezCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Enrique ColadoHematology and Laboratory Medicine Department and Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Central University Hospital of Asturias, Oviedo, Spain.
María Carmen ChillónCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
María Belén VidrialesCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Marcos GonzálezCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Daniel RiveraCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Carlos Salvador OsunaHematology Service, Miguel Servet Hospital, Zaragoza, Spain.
Teresa Caballero-VelázquezCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Vincent Van Der VeldenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Mojca Jongen-LavrencicDepartment of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Oliver GutiérrezHematology Service, Río Hortega Hospital, Valladolid, Spain.
Ana Yeguas BermejoHematology Service, University Hospital of Getafe, Madrid, Spain.
Luis García AlonsoHematology Service, University Hospital of Getafe, Madrid, Spain.
Monique Bourgeois GarcíaHematology Service, University Hospital, Valladolid, Spain.
Cristina De Ramón SánchezHematology Service, University Hospital, Valladolid, Spain.
Gloria García-DonasHematology Service, Juan Ramón Jiménez Hospital, Huelva, Spain.
Aránzazu García MateoHematology Service, Segovia General Hospital, Segovia, Spain.
Isabel RecioHematology Service, Nuestra Señora de Sonsoles Hospital, Avila, Spain.
Javier Sánchez-RealHematology Service, León Hospital, León, Spain.
Andrea MayadoCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
María Laura GutiérrezCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Paloma BárcenaCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Susana BarrenaCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Antonio LópezCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
Jacques Van DongenDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Alberto OrfaoCytometry Service (NUCLEUS), Department of Medicine, IBSAL and CIBERONC, Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain. orfao@usal.es.
Centro de Investigación Biomédica en Red de Cáncer · ESCentro de Investigación del Cáncer · ESInstituto de Investigación Biomédica de Salamanca · ESErasmus MC · NLHospital Universitario de Getafe · ESUniversidad de Valladolid · ESHospital de León · ESHospital General De Segovia · ESHospital Juan Ramón Jiménez · ESHospital Nuestra Señora de Alarcos · ESHospital Universitario Miguel Servet · ESHospital Universitario Río Hortega · ESInstituto de Investigación Sanitaria del Principado de Asturias · ESLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe hemorrhagic events occur in a significant fraction of acute promyelocytic leukemia patients, either at presentation and/or early after starting therapy, leading to treatment failure and early deaths. However, identification of independent predictors for high-risk of severe bleeding at diagnosis, remains a challenge. Here, we investigated the immunophenotype of bone marrow leukemic cells from 109 newly diagnosed acute promyelocytic leukemia patients, particularly focusing on the identification of basophil-related features, and their potential association with severe bleeding episodes and patient overall survival.From all phenotypes investigated on leukemic cells, expression of the CD203c and/or CD22 basophil-associated markers showed the strongest association with the occurrence and severity of bleeding (p ≤ 0.007); moreover, aberrant expression of CD7, coexpression of CD34

Indexed as

AdolescentAdultAgedAged, 80 and overBasophilsCell LineageChildChild, PreschoolFemaleHemorrhageHumansLeukemia, Promyelocytic, AcuteMaleMiddle AgedPhenotypeYoung Adult

Identifiers

PMID29572500
OpenAlexW2790904638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.